When reported, PSMA-targeted PET/CT showed a superior accuracy in tumor burden characterization, highlighting more metastatic lesions than conventional imaging, reducing false positive findings, and changing patient management in a substantial percentage of cases [29,30,31,35,38,40,42]. The gene discussed is FOLH1; the disease is neoplasm.